WILMINGTON, N.C., July 13 /PRNewswire-FirstCall/ -- PPD, Inc. today announced the appointment of Steadman Harrison, Ph.D., as senior research director and executive director of research and development of Piedmont Research Center, the company's preclinical cancer research division.
Harrison will direct the laboratories and lead a specialized team of scientists in conducting evaluations of anticancer therapies. His responsibilities include the design, conduct and interpretation of research studies in the areas of tumor biology, biochemistry and pharmacology. He also directs the quality assurance programs for the facility.
Prior to joining Piedmont Research Center, Harrison served as executive director of experimental medicine and executive director of business development at EMD Pharmaceuticals, Inc. (Merck KGaA). In previous roles, he was vice president of preclinical development at Sphinx Pharmaceuticals Corporation and director of cancer research and advisor of research acquisitions at Eli Lilly and Company.
He began his career with Southern Research Institute where he rose to the position of head of the pharmacology section and later served as director of chemotherapy research. He has served on the faculties of the University of Kentucky Graduate Center for Toxicology and the University of Alabama at Birmingham and is currently an adjunct faculty member of the Comprehensive Cancer Center at Duke University Medical Center.
"We are extremely pleased to attract a scientist of Steadman's caliber to direct our research activities," said Beth Hollister, vice president of Piedmont Research Center. "With an expertise spanning preclinical and clinical, he brings a wealth of knowledge about research and development of anticancer therapies, as well as an in-depth understanding of the needs of the pharmaceutical industry going forward."
Harrison holds a doctorate in pharmacology from Indiana University, having earned a bachelor of science from Mississippi State University and master of science in organic chemistry from Indiana University.
As a leading global provider of discovery and development services and products for pharmaceutical, biotechnology and medical device companies, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients maximize the return on their R&D investments. With proven early discovery through post-market resources, the company also offers compound partnering opportunities. PPD has more than 6,000 professionals in 27 countries around the world. For more information on PPD, visit our Web site at http://www.ppdi.com/ .
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the anticipated value and contributions of the above-named employee, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward- looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments; loss of large contracts; competition within the outsourcing industry; continued success in sales growth; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
+919 462 4088
+910 772 7585
CONTACT: Media, Nancy Zeleniak, +1-919-462-4088, email@example.com , or Analysts-Investors, Steve Smith,+1-910-772-7585, or firstname.lastname@example.org , both of PPD, Inc.